Experience with febuxostat in a patient with severe disabling gout
Gout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic tophaceous gout. Twelve-month therapy with dail...
Main Authors: | M. S. Eliseev, R. U. Shayakhmetova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/779 |
Similar Items
-
A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
by: Fengchun Zhang, et al.
Published: (2019-09-01) -
Management of hyperuricemia in gout: focus on febuxostat
by: Mattheus K Reinders, et al.
Published: (2010-01-01) -
The Clinical Effects of Febuxostat Alone or Combined with Arthroscopic Surgery for Gout: A Single-Center Retrospective Study
by: Gong Z, et al.
Published: (2021-09-01) -
Febuxostat: a new drug for an old disease. Do we really need it?
by: Giovanni Gulli, et al.
Published: (2013-04-01) -
Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01)